News
Zacks Investment Research on MSN3d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal UpdateKymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.
Kymera Therapeutics Announces Proposed Public Offering Provided by GlobeNewswire Jun 25, 2025, 8:05:00 PM. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback